ALX Oncology Holdings Inc. (ALXO)
Last updated: 2026-10-27 09:34:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
ALX Oncology Holdings Inc. (ALXO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.14, with a market capitalization of $161.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.86 to $2.66. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$161.78M | |
$1.19 | |
$117.45 | |
$0.40 | |
$1.17 | |
933.96K | |
1.18M | |
-- | |
$2.66 | |
$0.86 | |
-- | |
-- |
ALX Oncology Holdings Inc. (ALXO) Pre-Market Stock Price
ALX Oncology Holdings Inc. (ALXO) is trading at $1.18 in pre-market trading as of 2026-10-26 23:31:00, up 0.85% ($0.01) from the previous close of $1.17
Pre-market trading shows how investors are pricing ALXO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
ALX Oncology Holdings Inc. (ALXO) 7-Day Stock Price Change
Over the past seven days, ALX Oncology Holdings Inc. (ALXO) moved from $1.06 to $1.14, representing a gain of 7.08% ($0.07).
The stock traded between $0.93 and $1.30 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.06 million shares, down versus the previous seven-day period, indicating lower trading activity.
ALXO 52-Week Price Position
Position in Range: 15.2%
ALXO is currently trading at $1.14, placing it 15.2% of the way from its 52-week low of $0.86 to its 52-week high of $2.66. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is ALX Oncology Holdings Inc. (ALXO)?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
ALX Oncology Holdings Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 48 |
| Exchange | NASDAQ |
| Company Website |
How to Buy ALX Oncology Holdings Inc. (ALXO) Stock on MEXC
Eligible investors can buy real shares of ALX Oncology Holdings Inc. (ALXO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is ALX Oncology Holdings Inc. (ALXO) stock price today?
2.Is ALXO stock going up or down today?
3.What is ALXO pre-market price?
4.What is ALXO after-hours price?
5.Is ALXO stock trading now?
6.Where does ALXO sit relative to its 52-week high and low?
7.What sector is ALX Oncology Holdings Inc. in?
8.What is ALX Oncology Holdings Inc.'s market capitalization and where is it listed?
9.How is ALXO valued in terms of P/E ratio and EPS?
10.Does ALX Oncology Holdings Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ALXO Stock Calculator
Estimate the value between ALXO shares and USD.
ALXO Shares to USD
1.00 ALXO shares = 1.135 USD
Calculations are estimates based on the latest available price and are for reference only.



